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Abstract.  The integrin  VLA-2 was previously found 
to bind to either collagen alone,  or collagen plus lami- 
nin,  but the mechanism  for this  cell-specific functional 
difference was unknown.  Here we transfected VLA-2 
O/2 subunit cDNA into K562 cells and obtained VLA-2 
(called Form-O)  which bound to neither  collagen nor 
laminin.  We then used a  Matrigel  selection procedure 
to enrich  for a minor subpopulation  of K562 cells sta- 
bly expressing  a  form of VLA-2 (Form-C)  that bound 
to collagen but not laminin.  In contrast,  the same a 2 
cDNA transfected into  RD cells yielded VLA-2 
(Form-CL)  which bound to both collagen and laminin. 
These Form-O,  -C, and  -CL activities  were stably ex- 
pressed during  extended cell culture,  and could not be 
qualitatively altered by adding pborbol esters or by ex- 
changing  the resident divalent cations.  However, addi- 
tion of stimulatory  anti-El  antibodies  (TS2/16,  A-1A5) 
rapidly  converted VLA-2 Form-O and  Form-C  into 
Form-CL.  Anti-~t  antibody stimulation  of VLA-2 ac- 
tivity was observed not only on whole cells, but also 
with  solubilized  receptors.  These results  suggest (a) 
that  the ligand  binding  specificity of VLA-2 can be de- 
termined  by its cellular  environment,  rather  than  by 
variations  in the primary  sequence of the od subunit, 
(b) that  stably inactive or partly active VLA-2 can be 
rapidly  converted to a  fully active form through  con- 
formational  changes  initiated  at a  nonligand  binding 
site on the El  subunit,  and  (c) that  the mechanisms  for 
VLA-2 stimulation  by phorbol  ester and by antibody 
are quite distinct,  because the latter does not require 
an  intact  cell. 
T 
HE 20 or more distinct heterodimeric adhesion recep- 
tors in the integrin family mediate cell adhesion to an 
assortment  of extracellular  matrix  and  cell  surface 
proteins (20, 27, 52). Compounding the diversity of adhesive 
capabilities mediated by integrins, most, if not all integrins, 
can assume multiple functional states. On platelets (48, 57) 
and leukocytes (10, 14, 51, 59, 62), several integrins can exist 
in a relatively nonfunctional state until triggered to rapidly 
become functionally active.  The mechanism  for this rapid 
(and sometimes transien0  increase in integrin  function on 
different cells in response to a host of agonists is not clear. 
However, protein kinase C is undoubtedly involved because 
phorbol  esters  can  act  downstream  of specific  triggering 
pathways to cause upregulation of integrin functions (10, 50, 
61,  62).  When the cytoplasmic tails of the integrin ~2 and 
o/lIb chains have been deleted, the patterns of functional up- 
regulation  for o/LB2 (26)  and  for o/IIb~3 (43)  have been al- 
tered,  suggesting  that  a  connection  between  integrin  and 
cytoskeletal proteins plays a critical role. 
Integrin functions can be stimulated not only by phorbol 
esters  and  various  other  more  physiologically  relevant 
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agonists, but also by certain antibodies to the integrin B~ (4, 
32, 41, 58),/32 (29), and B~ (42) subunits. In some of these 
studies,  antibodies  were  suggested  to  modulate  integrin 
affinity by directly inducing a conformational change in the 
receptor at the cell surface (42), but in other cases, an active 
cellular metabolism was required (4, 32), suggesting that the 
anti-integrin  antibodies  could  possibly  have  an  indirect 
effect. 
In addition to having the flexibility to be turned on (and 
off),  certain  integrins  also  appear  to  undergo  cell-type 
specific regulation of adhesive capabilities. For example, on 
platelets and fibroblasts, the O/2B1 (VLA-2) integrin is a col- 
lagen receptor (33, 53, 55), whereas on many other cell types 
it is a receptor for both collagen and laminin  (15, 31,  35). 
The mechanism for this cell-specific variation is unknown, 
but  because  different  VLA-2  ligand-binding  specificities 
could be retained even in solution (31), it has been suggested 
that functional differences may be due to post-translational 
modifications, or even due to variations in the primary se- 
quences of the O/or 15 subunits. Cell type specific differences 
in VLA-3 functions have also been observed (18). 
To learn more about the mechanism for cell type specific 
regulation  of VLA-2 function,  we have expressed a  single 
O/2  cDNA  construct  in  two  different  cell  types,  to  yield 
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functional activity. Also, we made the surprising finding that 
these stable functional forms could be rapidly interconverted 
in the presence of appropriate stimulatory mAb, but not by 
the phorbol ester PMA. 
Materials and Methods 
Antibodies and other Proteins and Reagents 
Monoclonal antibodies utilized were: anti-VLA-2, 12FI  (47) and 5E8 (63); 
anti-VLA-5,  P1D6 (60);  anti-VLA-/~l,  A-1A5 (24),  TS2/16  (22),  and 41M 
(40); and the negative control antibodies P3 (37) and J-2A2 (23). Polyclonal 
antibody R812 directed against the COOH-terminal 22 amino acids of the 
integrin #1 subunit (3, 56) was obtained from Dr. A. E  Horwitz (Univer- 
sity of Illinois, Urbana, IL). Bovine type I collagen and Matrigel were from 
Collaborative Research Co. (Waltham, MA); human type I collagen was ob- 
tained from Telios Co.  (La Jolla, CA); and mouse laminin was obtained 
from Dr. Hynda Kleinman, National Institute of Dental Research, National 
Institutes of Health  (Bethesda,  MD).  Collagen-Sepharose and  laminin- 
Sepharose (each at "-0.5 mg/ml packed beads) were prepared by coupling 
bovine type I  collagen or  mouse laminin to  CNBr-activated Sepharose 
(Pharmacia LKB Biotechnology, Piscataway,  NJ) according to the manufac- 
turer's instructions. 
Cell Lines 
Full-length eDNA for the VLA et  2 subunit (54)  in the mammalian expres- 
sion vector pFneo (9, 44, 49) was used for stable transfection of K562 (16) 
and RD (9) cells as previously described. As previously determined, back- 
ground integrin levels did not change upon t~  2 expression. K562 cells con- 
tinued to express us, but not ct  1, t~  3, a 4, or t~  6 (16),  and lid and RDA2 
cells both expressed equivalent moderate levels of cd and c~  4, trace levels 
of cr 5 and c~  6 and no detectable t~  3 (9).  Transfected cells were maintained 
in RPMI 1640  supplemented with 10%  FBS, L-glutamine and antibiotics 
in the continuous presence of geneticin (G-418 sulfate, Gibco Laboratories, 
Grand Island, NY) at  1 mg/ml. 
Flow Cytometry and Matrix Adhesion Assay 
Indirect immunofluorescence staining was performed using mAb against 
VLA protein subunits and then flow cytometric analyses were performed 
using a FACScan machine as described previously (16). Cell attachment to 
matrix proteins collagen, laminin and fibronectin was carried out in the 
presence or absence of stimulating or blocking antibodies as described pre- 
viously (7).  Briefly, cells were labeled by incubation with the fluorescem 
dye BCECF (Molecular Probes, Inc., Eugene, OR), and then 5 x  104 cells 
(in RPMI media) were added to 96-well microtiter plates (Flow Labs, Inc., 
McLean, VA) that had been coated with protein ligands and blocked with 
0.1% BSA. After 25-30 min incubation, unbound cells were removed (2-3 
washes with RPMI media). Then, cells remaining attached to the plate were 
analyzed using a Fluorescence Concentration Analyzer machine (IDEXX 
Co.,  Portland,  ME).  Background  binding  (assessed using  BSA-coated 
wells) was typically <5 % of the total, and results are reported as the mean 
of triplicate determinations +1  SD. 
Immunoprecipitation and Receptor Isolation 
Using CoUagen-Sepharose 
Cells were surface labeled with 1251 using lactoperoxidase and lysed in the 
presence of 0.5%  Nonidet P-40 (NP-40). Then immunoprecipitation and 
SDS-PAGE analyses (on 6% polyacrylamide gels) were carried out as previ- 
ously  described (21).  For  collagen-Sepharose experiments,  t25I-labeled 
cells were solubilized in 0.1 M Octyl-/3-o-thioglucopyranoside  (OSPG, Cal- 
biochem Corp., La Jolla, CA), 0.1 M n-Octyl-/5-D glucopyranoside (OPG, 
Sigma Chemical Co., St. Louis, MO) 0.1 mM MnC12 and protease inhibi- 
tors PMSF, leupeptin, and aprotinin in PBS  for  1 h  at 4~  Collagen- 
Sepharose and laminin-Sepharose (each at "~0.5 mg/mi packed beads) were 
prepared by coupling bovine type I collagen (Telios Pharmaceuticals, Inc., 
San Diego, CA) or mouse laminin to CNBr-activated Sepharose (Pharmacia 
LKB Biotechnology) according to the manufacturer's instructions. 
Results 
From previous experiments, it was clear that transfection of 
t~  2 into the rhabdomyosarcoma cell line RD resulted in ex- 
pression of VLA-2 (here called Form-CL) that bound to both 
collagen and laminin (8, 9). To determine whether other c~  2 
recipient cells would also express VLA-2 with Form-CL ac- 
tivity, o~  2 eDNA was  transfected into the erythroleukemic 
cell line K562. After transfection, selection and enrichment, 
homogeneous populations  stably  expressing VLA-2  were 
obtained. Although they displayed moderate to high levels 
of cell surface VLA-2 (see Fig. 3 below), these cells (named 
KA2) consistently showed minimal adhesion to either colla- 
gen  or  laminin,  comparable  to  that  of mock-transfected 
K562 (KpF) cells (Fig. 1 A). Attempts were made to increase 
ligand binding activity by adding phorbol esters (50 nM, for 
15 min before assay), but only marginal improvements were 
observed (not shown). Also, attachment assays were carried 
out in the presence of 1 mM Mg  §247  or 0.1-1 mM Mn  §  but 
still no consistent increase in adhesion was observed (not 
shown). To indicate its lack of functional activity, the VLA-2 
molecule on these cells is called "Form-O". 
To attempt enrichment for c~2-transfected K562 cells that 
might display VLA-2 functional activity, a Matrigel selection 
procedure  was  carried  out.  After  4  wk  of  culture  on 
Matrigel, the vast majority of cells failed to adhere and di- 
vide (Fig.  2 A).  However, a few rare cells adhered to the 
Matrigel and then those cells proliferated to form large ad- 
herent cell colonies (Fig.  2  B).  After expansion of these 
selected Matrigel-adherent colonies using normal tissue cul- 
ture conditions (i.e., in the absence of Matrigel), they were 
tested for VLA-2-mediated adhesion functions. In compari- 
son to the unselected KA2 cells, two Matrigel-selected cell 
cultures (KA2-M1 and KA2-M2, originating from distinct 
colonies) showed over 15-fold greater cell attachment to col- 
lagen, although they still bound minimally to laminin (Fig. 
1 B). Notably, this enhanced binding to collagen persisted 
even after several additional  months  of continuous tissue 
culture. 
As shown (Fig. 1 C), phorbol ester treatment of KA2-MI 
and KA2-M2  cells caused a  two to threefold increase in 
adhesion to collagen, but adhesion to laminin still remained 
near the  background  levels observed in mock-transfected 
K562 cells (KpF). Thus, in contrast to VLA-2 expressed in 
cd-transfected RD cells, which mediates adhesion to both 
collagen and laminin  (Fig.  1 D  and references 8  and 9), 
VLA-2  expressed in  K562  cells  displayed only collagen- 
binding activity. Because VLA-2 on the Matrigel-selected 
cells  (KA2-M1,  -M2) bound to only collagen,  it was  de- 
scribed as having "Form-C" in contrast to VLA-2 on RDA2 
cells which had Form-CL activity. 
Analysis of VLA-2 expression by flow cytometry (Fig. 3) 
showed that KA2 cells (Form-O) and KA2-M2 cells (Form- 
C)  expressed comparable amounts of cell surface VLA-2 
(detected by mAb 12F1), whereas no VLA-2 was detected on 
mock-transfected (KpF) cells. Three other anti-VLA-2 mAbs 
gave almost identical results (not shown).  Levels of the/3t 
subunit were increased on KA2 and KA2-M2 cells compared 
to KpF, consistent with there being an increase in the total 
amount of ct subunit at the cell surface.  Levels of VLA-5 
were not appreciably different between KpF, KA2, and KA2- 
The Journal  of Cell Biology,  Volume 120, 1993  538 400 
E 
300  t- 
D 
0 
.(3 
--~200 
0 
100 
Unsetected  A 
[]  collagen 
￿9  laminin 
Matrigel-  B  Matrigel- 
Selected  Selected 
+ PMA 
C  Unselected  O 
Figure 1.  Multiple  functional  forms of VLA-2 derived  from the 
same a 2 cDNA. (A) Cell attachment to collagen and laminin was 
tested for mock-transfected K562  (KplO and a2-transfected  K562 
cells  (KA2) cells.  (B and  C) After selection  for attachment and 
growth on Matrigel (see Fig. 2 legend),  two independently  isolated 
subclones of KA2 cells  (KA2-M1  and KA2-M2) were tested  for 
adhesion after a  15 min pretreatmeut with  50 nM PMA (C),  or 
without  PMA treatment  (B). (D) Unselected  txZ-transfected (RDA2) 
cells were also tested for adhesion to collagen and laminin.  Plastic 
surfaces in 96-well plates were coated with laminin at 10 #g/ml (A), 
2.5/~g/ml (B and C), or 3/~g/ml (D);  or collagen at 2/~g/ml (A), 
2.5/~g/ml (B and C), or 1/zg/ml (D). Multiple  other doses of colla- 
gen and laminin were tested and yielded the same relative patterns 
of adhesion (not shown).  Doses of collagen and laminin used for 
D are sufficiently low so that background adhesive contributions  of 
VLA-1 and VLA-6 are minimal. 
M2 ceils,  and the cx  t,  cx  3, #,  and o~  6 subunits  remained es- 
sentially undetectable on these cells. Levels of VLA-2 shown 
here  are  comparable  to  those  previously  shown  on  o~  2- 
transfected RDA2 (form CL) cells (8 and 9). Thus, the func- 
tional differences between VLA-2 Form-O, -C and -CL seen 
in Fig. 1 can not be explained on the basis of variable expres- 
sion levels. 
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Figure 3.  Surface expression  of a 2,  a 5,  and  fit  subunits  on a 2- 
transfected  K562 cells.  Mock-transfected  and cd-transfected  (KA2 
and  KA2-M2) cells  were stained  with  control MAb P3  (dotted 
line),  anti-a  s MAb  12F1, anti-a  s MAb P1D6, and anti-~  MAb 
A-1A5, and then measured by flow cytometry. 
To further compare Form-O, Form-C, and Form-CL, the 
VLA-2  heterodimer  was  immunoprecipitated  from  KA2, 
KA2-M2,  and RDA2 cells  (Fig.  4).  As shown,  the anti-~x  2 
antibody  12F1  recognized  o~2flit heterodimers  from  KA2 
(lane b), KA2-M2 (lane c), and RDA2 (lane e) cells that were 
essentially  indistinguishable,  whereas  no  VLA-2  subunits 
were seen in mock transfected cells  (lanes a  and d). 
The human fiit subunit may exist in alternatively  spliced 
forms in which the COOH-terminal  22  amino acids of fit 
are replaced by either  12 (2) or 48  (36) amino acids from 
different exons (2).  To determine whether different alterna- 
tively  spliced  forms  of fit  might  correlate  with  different 
functional forms of VLA-2, we carried out immunoprecipi- 
tations utilizing rabbit antiserum specifically recognizing the 
COOH-terminal 22 amino acids of"nonalternatively spliced" 
fit. The result (not shown) was that most, if not all of the fit 
subunit was in the nonalternatively spliced form in the K562 
cells, RD cells, and other cells with Form-C or Form-CL ac- 
Figure  2.  Selection  of aZ-K562  transfectants  exhibiting  stable 
VLA-2/collagen binding  activity,  a2-transfected  K562  cells  dis- 
playing moderate to high VLA-2 expression  but minimal collagen 
or laminin binding activity were added to plastic wells coated with 
1 ml of Matrigel  (1  x  107 cells/well  of a 6 well plate).  After 4 w 
of culture in the presence of selective media ((3418, 2 mg/ml), the 
majority of cells remained loosely adherent or non-adherent (A), 
but an occasional colony of adherent cells  was observed (B). 
Figure 4. Immunoprecipitation  of VLA-2 
~x  2  and  fit  subunits  from  transfected 
cells. Equivalent amounts of KpF, KA2, 
KA2-M2, RDpF, and RDA2 cells were 
radiolabeled  with  t25I, extracted  with 
NP-40,  and  then  immunoprecipitated 
using the anti-VLA-2 MAb 12FI (lanes a, 
e). The negative control antibody J-2A2 
yielded blank lanes from each cell extract 
(not shown). 
Chan  and  Hemler  Three Functional Forms of VLA-2  539 bTgure  5. Upregulation of  VLA-2 functional activity induced by MAb 
TS2/16. As indicated, KpE KA2, or KA2-M2 cells were allowed to 
adhere to collagen (A) or laminin (B) in the presence of negative con- 
trol antibody, the stimulatory antibody TS2/16, or TS2/16 plus the 
anti-cd inhibitory antibody 5E8. 
tivity.  In conclusion,  there were no obvious differences in 
VLA-2 structure or expression that could be correlated with 
Form-O, -C or -CL functional activities. 
Recent results have shown that certain anti-El antibodies 
can cause a dramatic increase in VLA protein function (4, 
32, 41,  58), possibly by causing a favorable conformational 
change. Here we investigated the effect of one such antibody 
(TS2/16) on VLA-2 function in K562 cells. As shown (Fig. 
5  A)  the  MAb  TS2/16  caused  a  substantial  increase  in 
collagen-mediated  adhesion  by  both  KA2  (63-fold)  and 
KA2-M2 cells (12-fold)  compared to cells stimulated with a 
control  MAb  (P3).  For laminin binding  (Fig.  5  B),  even 
greater relative increases were seen (>500-fold for KA2; 70- 
fold for KA2-M2 cells). Thus, the TS2/16 MAb appeared to 
convert both Form-O and Form-C activity of VLA-2 in K562 
cells  into  Form-CL  activity,  comparable  to  that  seen  in 
RDA2  and  other  cells.  Another  anti-~  antibody  (A-1A5) 
had a similar stimulatory effect on KA2 and KA2-M2 cells 
(not shown), and both TS2/16 and A-1A5 could stimulate the 
function of VLA-5 endogenously  expressed in K562  cells 
(not shown). When TS2/16 was added to RDA2 cells, adhe- 
sion to both collagen and laminin was again increased, but 
only by ,~twofold (not shown). 
In comparison to TS2/16,  the phorbol ester PMA yielded 
minimal enhancement of VLA-2 adhesion to either collagen 
or laminin (Fig. 5, A and B), although a stimulatory effect 
was  more  obvious  when  PMA  was  added  together  with 
TS2/16.  Importantly, the MAb TS2/16 and PMA-stimulated 
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bi'gure 6. Effects of titrated MAb TS2/16 and PMA on VLA-2 func- 
tion in K562 cells. Increasing  doses of  control antibody, TS2/16, PMA, 
or TS2/16 plus PMA were added to KA2 cells as indicated, and then 
after 15 min incubation, adhesion to collagen or laminin was tested. 
activity was completely inhibited  by the anti-VLA-2 MAb 
5E8 (Fig. 5, A and B) or by the anti-~t antibody 4B4, thus 
confirming that the enhanced adhesion was indeed mediated 
through VLA-2. When added to RDA2 cells, PMA had al- 
most no detectable effect (not shown). 
To compare PMA and TS2/16 effects in more detail, both 
agents were titered,  alone or together on KA2 cells, up to 
a maximally effective dose (Fig. 6). As shown, for adhesion 
to either collagen (Fig. 6 A) or laminin (Fig. 6 B), PMA was 
not nearly as stimulatory as TS2/16.  For adhesion to colla- 
gen,  effects  of PMA  and  TS2/16  were  roughly  additive, 
whereas for adhesion to laminin, PMA appeared to act syn- 
ergistically with TS2/16.  In the latter case, PMA had mini- 
mal effect alone, but induced a substantial increase in adhe- 
sion when TS2/16 was also present.  These results provide 
good further evidence for differences in the mechanisms for 
VLA-2 mediated binding to collagen compared to laminin. 
To determine whether TS2/16 stimulation required a cel- 
lular context,  or could act on soluble receptors, collagen- 
Sepharose binding  experiments were carried  out.  Lysates 
from KA2 cells were incubated with either TS2/16 or the 
control mAb J-2A2, and then passed over identical collagen- 
Sepharose columns. Analysis of VLA-2 in both the unbound 
flowthrough material and  material eluted  with EDTA was 
carried out by immunoprecipitation using the anti-or 2 mAb 
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TS2/16. (A) ~25I-radiolabeled cell lysate from KA2 cells (~5  x 
106 cell equivalents) was incubated with MAb TS2/16 (lanes b, d) 
or with control MAb J-2A2 (lanes a, c), and then added to collagen- 
Sepharose columns (2 ml of packed beads). After 4 h incubation 
at room temperature, unbound flow  through material (F/) was re- 
moved by washing columns with ,,A0 ml of 25 mM OSGP, 25 mM 
OGP, 0.5 mM NaC1 (wash buffer), and then bound VLA-2 was 
eluted by adding wash buffer containing 20 mM EDTA. Fractions 
(0.5 ml) containing peak radioactivity were collected and then the 
MAb 12F1 was used to immunoprecipitate VLA-2 from unbound 
(lanes a, b) and from EDTA-eluted  fractions (lanes c, d). (B) In a 
separate experiment, KpF, KA2, and KA2-MT2 cell lysates were 
immunodepleted of background proteins by incubation with MAb 
J-2A2, followed by protein A-Sepharose. Then either J-2A2 (lanes 
e-g) or TS2/16 (lanes h-j) was added, and lysates were incubated 
batchwise with 0.1 ml of collagen-Sepharose beads (18 h, at 4~ 
After washing with ,,08 ml of wash buffer, specifically bound pro- 
teins were eluted using SDS-sample buffer and analyzed by SDS- 
PAGE as indicated. 
12F1. As shown (Fig. 7 A), the VLA-2 from the lysate in- 
cubated with J-2A2 was almost entirely in the unbound frac- 
tion (lane a),  and not detectable in the specifically eluted 
fraction (lane c), consistent with this integrin being function- 
ally inactive. In contrast, a large proportion of VLA-2 from 
the TS2/16-treated KA2  lysate was  present  in  the EDTA- 
eluted fraction (lane d) compared to the flowthrough fraction 
(lane b). 
To assure that TS2/16 antibody bound to VLA-2 was not 
somehow selectively contributing to VLA-2 immunoprecipi- 
tation in the collagen-EDTA eluate, another experiment was 
carried out in which immunoprecipitation was not utilized 
(Fig. 7 B). Equivalent amounts of cell lysate were incubated 
batchwise with collagen-Sepharose in the presence of either 
control antibody J-2A2 or TS2/16,  and then after washing, 
the total radioactivity bound to the collagen-Sepharose was 
analyzed. As shown, TS2/16 caused markedly greater VLA-2 
binding to collagen-Sepharose (lanes i and j) than did J-2A2 
(lanes f  and g). Collagen-Sepharose did not bind to any de- 
tectable VLA proteins from mock-transfected cells regard- 
less of antibody incubation (lanes e and h). Because VLA-5, 
present  in  the  mock-transfected  cells,  did  not  bind  to 
collagen-Sepharose, this  further indicates that TS2/16 did 
not cause non-specific trapping of/3~ containing integrin. In 
additional  control  experiments  (not  shown),  the  anti-o~  2 
MAb  12F1 did not promote VLA-2 binding  to  collagen- 
Sepharose,  and  the  anti-/~  MAb  4B4  caused  diminished 
binding of VLA-2 (to below the low level sometimes seen 
with  J-2A2),  consistent  with  its  known  anti-B~ integrin 
adhesion properties.  In  further analysis of VLA-2  solubi- 
lized from KA2  cells,  we  found that binding to laminin- 
Sepharose columns was also stimulated by the addition of 
TS2/16 antibody (not shown), consistent with the cell adhe- 
sion results shown in Fig.  5 B. 
Discussion 
In highly controlled experiments, using a  single t~  2 eDNA 
construct, we have been able to express VLA-2 in multiple 
functional forms (Forms-O, -C, -CL). In each case, the cd 
subunit was expressed at similar levels and the ct  2 and/~ 
subunits  showed no detectable differences in biochemical 
structure or in epitopes detected by various antibodies. Re- 
markably, Forms-O and -C could be rapidly converted to 
Form-CL upon  addition  of the  anti-/31 MAb  TS2/16.  To- 
gether, these findings suggest that the observed variations in 
VLA-2 functions are not caused by differences in the primary 
sequence of ~2, by post-translational modifications of VLA-2 
subunits, or by some other inherent deficiency in the struc- 
ture of the molecules. Instead, it appears that VLA-2 in dis- 
tinct cellular environments can assume different stable, but 
interconvertible conformations corresponding to  different 
functional activities. 
Not only was each form consistently maintained for many 
months in cultured cells, but also the corresponding func- 
tional phenotype was retained when VLA-2 was solubilized. 
In this regard, previous studies have also shown that VLA-2 
could retain the equivalent of either Form-C or Form-CL ac- 
tivity (depending on cell source) when solubilized, purified, 
and then tested in column binding assays (31) or reconsti- 
tuted into liposomes (53). The challenge now remains to un- 
derstand how different functional forms might be stably pro- 
duced, maintained in the absence of intact cells, and yet be 
susceptible to conversion to a more active state by an anti- 
/31 MAb. 
Several factors have previously been suggested to modu- 
late the activation state of integrins and/or their ligand spec- 
ificity.  For  example,  the  phospholipid  environment  was 
reported to influence the ligand specificity of the integrin 
ave3  (11), an unidentified lipid  appeared to modulate the 
function of ctM/32 (25),  and  t~/3,  appeared  to  function in 
concert with chondroitin sulfate proteoglycan (28). For the 
VLA-2 results observed here, modulation by lipid factors or 
protcoglycans seems unlikely because ligand specificity is 
retained for detergent solubilized receptors. Also, divalent 
cations have been found to markedly influence the ligand 
specificity of several integrins (17, 30, 34), including VLA-2 
(19, 53). However, in our studies up to 1 mM of the cations 
(Mn  ++,  Mg  ++) known to facilitate VLA-2 function did not 
convert VLA-2 Form-O or Form-C into more active forms. 
The a  chain cytoplasmic domain appears to play a key role 
Chan and Hemler  Three  Functional Forms of VLA-2  541 in determining the functional state of cdtb/~3 when expressed 
in CHO cells because deletion or exchange of that domain 
led to increased ligand binding (43). However, we have found 
that exchange of ct  2 cytoplasmic tails did not alter Form-CL 
activity when expressed in RD cells (8),  and did not alter 
Form-O or Form-C activity when expressed in K562 cells 
(not shown).  In another study, variations in glycosylation 
have been  suggested to  possibly regulate the  function of 
VLA-5 (as~t) (1). However, considering that (a) no obvious 
variation in the size of VLA-2 subunits was observed,  (b) 
treatment with a variety of inhibitors of N-linked carbohy- 
drate processing had no consistent effect on VLA-2 function 
(not shown) and (c) VLA-2 functions could be rapidly al- 
tered by adding the TS2/16 MAb, it does not seem highly 
likely that glycosylation differences would account for the 
observed variations in VLA-2 function. 
Because we were able to select a  stable  subline of a 2- 
transfected K562 cells with increased collagen binding activ- 
ity, it appears that K562 cells are not totally incapable of sup- 
porting basal VLA-2 activity. Also in this regard, others have 
found that induction of K562 cells along the megakaryocytic 
pathway could induce expression of  VLA-2 with ample colla- 
gen binding activity (6). 
By a process termed "inside out" signaling, many stimuli, 
acting through a variety of receptors, can cause a rapid up- 
regulation of the function of/3~ (10, 12, 51, 61),/~2 (14, 45, 
59, 62),  and/33  (5,  38) integrins without a change in inte- 
grin expression. Because phorbol esters such as PMA can 
mimic the integrin-activating effect of many diverse stimuli 
(10, 12, 14, 45, 51, 59, 61, 62), PKC has been invoked as hav- 
ing  a  critical  role  in  integrin  activation.  In  the  results 
reported in this paper,  TS2/16  had a dramatic stimulatory 
effect, that could not be achieved by adding PMA. Thus, be- 
cause TS2/16 could act in solution, and could not be mim- 
icked by PMA, it perhaps suggests that there may be an es- 
sential component of the activation process that does not 
require PKC, and cannot be overcome by adding PMA. Also, 
in this regard, we have found that deletion of the cytoplasmic 
domain of tx  4 abolishes PMA stimulation but not TS2/16 
stimulation of VLA-4-mediated adhesion (P.  Kassner, M. 
Hemler, manuscript in preparation). It is intriguing to specu- 
late that TS2/16 could mimic an unknown extracellular fac- 
tor that may activate integrin function independent of mecha- 
nisms involving intracellular metabolism. Consistent with 
this idea, peptides containing integrin recognition sequences 
were found to directly activate the integrin tXHb/~3 (13). 
The finding by others that FAb fragments of TS2/16 could 
stimulate the function of VLA-4, VLA-5 and VLA-6 (4, 58) 
indicates that receptor cross-linking is not critical, but in- 
stead favors a mechanism involving a direct induction of a 
conformational change by the antibody. Supporting this, the 
function of solubilized o/Ilb~3  has  also  been  found to  be 
directly stimulated by an anti-fl subunit antibody (42).  Our 
results argue against the suggestion by others that stimulation 
by anti-ill MAbs requires an intact cytoskeleton and an ac- 
tive cellular metabolism (4, 32, 58). Most likely, inhibitors 
of energy dependent functions (NAN3 and 2-deoxyglucose) 
as  well  as  cytoskeletal disruptors  (cytochalasin B)  were 
effective in abolishing post-ligand binding events needed for 
cell adhesion rather than influencing conformation changes 
in the receptor itself induced by fl~ MAbs. 
While we observed that partly activated VLA-2 could bind 
to collagen but not laminin, it is notable that increased VLAo2 
binding to laminin was observed in parallel with elevated 
collagen binding, and in fact, we have never observed VLA- 
2-mediated adhesion to laminin without adhesion to collagen 
being at least as high. These findings with VLA-2 are per- 
haps  reminiscent of those  for cdr~  which in  its poorly 
active state can only recognize immobilized fibrinogen but 
in  a  more  active  state  can  recognize  soluble  fibrinogen, 
fibronectin and other ligands (46).  Similarly, partly active 
VLA-4 can mediate adhesion to VCAM-1 but not to the CS1 
region of fibronectin, whereas fully active VLA-4 can adhere 
well to both ligands (39).  Thus, it may be a common theme 
among integrins that expanded ligand specificity can occur 
in parallel with increased activation; a mechanism whereby 
additional flexibility and versatility can be achieved through 
only a single type of receptor. Future studies will hopefully 
shed more light on the reasons why it might be advantageous 
to have a higher threshold for activation of VLA-2 mediated 
adhesion to laminin, as compared to the more readily ob- 
tainable adhesion to collagen. 
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